AI evidence summary · MVP
Curcumin for Osteoarthritis
AI preliminary evidence assessment
BB 級｜AI 整體初步評級
This preliminary assessment is currently available in Traditional Chinese.
Exact question對成人膝骨關節炎患者，口服單方薑黃素或薑黃類素作為症狀治療，相較於安慰劑、相同共照或活性對照，是否改善疼痛或身體功能，並有哪些不良反應？
已驗證評讀顯示研究結果偏向支持介入效果，但仍有重要不確定性。主要限制包括：全部納入來源僅依摘要評讀，未完成全文擷取；未報告的資助、利益衝突、停藥、罕見傷害及長期傷害均不可推論；17篇直接報告至少對應16個獨立支持單位；兩篇使用同一ISRCTN10074826登錄，不能當作兩個獨立世代重複計數。
Why this assessment was given
- NR-INF-02相較安慰劑顯著降低VAS疼痛與WOMAC功能相關分數，並減少救援藥物使用。
Limitations affecting this assessment
- 17篇直接結果報告僅代表至少16個獨立試驗族群；兩篇共用ISRCTN10074826，不可重複計入參與者。
- 全部直接來源均限於摘要，未完成全文擷取，因此隨機化細節、分配隱蔽、盲法、遺失資料、選擇性報告、完整劑量組成、共介入及退出原因多無法充分核實。
- 製劑高度異質，包括一般萃取物、Theracurmin、Aquasome、BCM-95、固體脂質顆粒、奈米微胞、水分散型及其他增進生體可用率技術；每日劑量約80至1500 mg、療程約4至12週，不能視為可互換或推廣至所有產品。
- 部分研究樣本小、單中心、屬先導研究或開放標籤；活性對照與非劣性結果不能取代具充分檢定力的安慰劑對照效益估計。
- 疼痛結果較一致；功能結果雖多有改善，但並非所有量表或客觀功能測試均呈現組間差異。
- 不良事件與停藥資料報告不完整且追蹤短；僅能評估常見短期耐受性，不能推論罕見、嚴重或長期傷害。
- 至少一項研究揭露大學與產品公司資助；其餘來源未述及者不得推定無產業資助或利益衝突。
- 六筆來源因資訊不足仍為未解背景，不作直接療效或傷害證據；含胡椒鹼的研究及系統性回顧僅作背景，未增加獨立參與者。
- 主要登錄資料記載總收案139人；PMID 32311961摘要報告140人，差異無法由摘要解釋。本評級將兩份報告視為同一試驗unit，只計一次；兩份報告的結果與限制仍分別呈現。
Research results
Findings are currently provided in Traditional Chinese; source excerpts retain their original language.
Main result 1
42 天NR-INF-02相較安慰劑顯著降低VAS疼痛與WOMAC功能相關分數，並減少救援藥物使用。
Applicability assessment: 原發性疼痛性膝骨關節炎的薑黃萃取物試驗。
- Population
- 原發性膝骨關節炎患者
- Intervention
- NR-INF-02，每次 500 mg、每日 2 次
- Comparator
- 安慰劑
- Outcome
- 相較安慰劑，VAS、WOMAC 與 CGIC 治療後分數顯著下降。
- Follow-up
- 42 天
- Formulation
- Not established
- Dose
- NR-INF-02 500 mg，每日2次
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 2
3 個月三個月時VAS無差異；KOOS疼痛與日常功能僅呈較佳趨勢，所有組間差異均未達統計顯著。
Applicability assessment: 在相同雙氯芬酸治療下評估薑黃素加成效果。
- Population
- 原發性膝骨關節炎患者
- Intervention
- 薑黃素每日 1,000 mg，加雙氯芬酸
- Comparator
- 雙氯芬酸加安慰劑
- Outcome
- 兩組 VAS 疼痛評分無差異。
- Follow-up
- 3 個月
- Formulation
- Not established
- Dose
- 薑黃素1,000 mg/日，加雙氯芬酸75 mg/日
Source excerpt: There was no difference in VAS [p-value = 0.923 (F = 0.009)].View source
Main result 3
4 週WOMAC總分、疼痛及功能相對布洛芬達非劣性；僵硬未達非劣性檢定顯著。
Applicability assessment: 原發性膝骨關節炎與布洛芬的活性對照試驗。
- Population
- 原發性膝骨關節炎患者
- Intervention
- Curcuma domestica 萃取物每日 1,500 mg
- Comparator
- 布洛芬每日 1,200 mg
- Outcome
- 第 4 週 WOMAC 總分、疼痛與功能相對布洛芬達非劣性；僵硬分量表未達顯著。
- Follow-up
- 4 週
- Formulation
- Not established
- Dose
- Curcuma domestica萃取物1,500 mg/日
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 4
6 週相較安慰劑，WOMAC、VAS及LPFI改善較大；WOMAC疼痛與身體功能改善，僵硬無顯著差異。
Applicability assessment: 輕至中度膝骨關節炎的薑黃類素安慰劑對照試驗。
- Population
- 輕至中度膝骨關節炎患者
- Intervention
- 薑黃類素每日 1,500 mg，分 3 次服用
- Comparator
- 相配安慰劑
- Outcome
- 相較安慰劑，WOMAC、VAS 與 LPFI 分數下降幅度較大。
- Follow-up
- 6 週
- Formulation
- Not established
- Dose
- 薑黃類素1,500 mg/日，分3次
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 5
8 週第8週膝痛VAS低於安慰劑，但基線VAS極低者例外；功能量表的組間結果未在摘要明確報告。
Applicability assessment: 特定水分散型薑黃素製劑用於膝骨關節炎。
- Population
- 40 歲以上、Kellgren-Lawrence II 或 III 級膝骨關節炎患者
- Intervention
- Theracurmin，每日含薑黃素 180 mg
- Comparator
- 安慰劑
- Outcome
- 第 8 週膝痛 VAS 低於安慰劑；初始 VAS 不高於 0.15 者除外。
- Follow-up
- 8 週
- Formulation
- Not established
- Dose
- Theracurmin，每日含薑黃素180 mg
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 6
總WOMAC、各分量表及VAS相較安慰劑均有統計顯著改善。
Applicability assessment: Curene 是以 Aquasome 技術製成的膝骨關節炎試驗製劑。
- Population
- 40 至 75 歲膝骨關節炎患者
- Intervention
- Curene，每日 500 mg
- Comparator
- 安慰劑
- Outcome
- 相較安慰劑，WOMAC 總分及分量表、VAS 自基線的下降達統計顯著。
- Follow-up
- Not established
- Formulation
- Not established
- Dose
- Curene 500 mg，每日1次
Source excerpt: The reduction from baseline in total WOMAC score (also subscale scores) and VAS score resulted in statistically significant difference when compared to placebo.View source
Main result 7
28 天疼痛與KOOS改善和雙氯芬酸相似且差異不顯著；摘要未提供正式非劣性界值。
Applicability assessment: 膝骨關節炎的 BCM-95 與雙氯芬酸活性對照試驗。
- Population
- 膝骨關節炎患者
- Intervention
- BCM-95 薑黃素每次 500 mg、每日 3 次
- Comparator
- 雙氯芬酸每次 50 mg、每日 2 次
- Outcome
- 第 14 與 28 天，疼痛及 KOOS 改善與雙氯芬酸組的差異未達統計顯著。
- Follow-up
- 28 天
- Formulation
- Not established
- Dose
- BCM-95薑黃素500 mg，每日3次
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 8
90 天完成者分析顯示VAS及WOMAC顯著改善，摘要稱與布洛芬療效相當，但未給組間估計或非劣性檢定。
Applicability assessment: 固態脂質薑黃素顆粒製劑與布洛芬的活性對照試驗。
- Population
- 膝骨關節炎患者
- Intervention
- Longvida 固態脂質薑黃素顆粒，每次 400 mg、每日 2 次
- Comparator
- 布洛芬加安慰劑，每日 1 次
- Outcome
- 完成者的 VAS 與 WOMAC 分數顯著改善；摘要稱其緩解疼痛的效果與布洛芬相當。
- Follow-up
- 90 天
- Formulation
- Not established
- Dose
- Longvida SLCP 400 mg每日2次，每粒提供薑黃素80 mg；每日薑黃素160 mg
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 9
3 個月第90日兩劑量組疼痛降幅均大於安慰劑；整體KOOS隨時間改善，但各組變化相近。
Applicability assessment: 症狀性膝骨關節炎的兩種劑量生體最佳化薑黃萃取物試驗。
- Population
- 膝骨關節炎患者
- Intervention
- 低劑量或高劑量生體最佳化薑黃萃取物
- Comparator
- 安慰劑
- Outcome
- 第 90 天，低劑量與高劑量組的疼痛降幅均大於安慰劑組。
- Follow-up
- 3 個月
- Formulation
- Not established
- Dose
- 生體最佳化Curcuma longa萃取物低劑量或高劑量；摘要未報告毫克數
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 10
6 週相較安慰劑，WOMAC總分、疼痛、僵硬及身體活動分量表均顯著下降。
Applicability assessment: 奈米微胞薑黃素用於膝骨關節炎。
- Population
- 膝骨關節炎患者
- Intervention
- 奈米薑黃素每 12 小時 40 mg
- Comparator
- 不含薑黃素的相似膠囊安慰劑
- Outcome
- 相較安慰劑，WOMAC 總分及疼痛、僵硬、身體活動分量表均顯著下降。
- Follow-up
- 6 週
- Formulation
- Not established
- Dose
- 奈米薑黃素40 mg，每12小時1次
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 11
28 天加用薑黃類素在KOOS疼痛及生活品質上優於單用雙氯芬酸，且救援止痛藥使用較少。
Applicability assessment: 在相同雙氯芬酸治療下評估加用 BCM-95 薑黃類素。
- Population
- 膝骨關節炎患者
- Intervention
- BCM-95 薑黃類素複合物加雙氯芬酸
- Comparator
- 單用雙氯芬酸
- Outcome
- 相較單用雙氯芬酸，加用薑黃類素的 KOOS 疼痛及生活品質改善較大。
- Follow-up
- 28 天
- Formulation
- Not established
- Dose
- BCM-95薑黃類素複合物500 mg加雙氯芬酸50 mg，每日2次
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 12
12 週VAS與WOMAC膝痛優於安慰劑，但積液滑膜炎體積及軟骨組成沒有改善。
Applicability assessment: 研究對象同時有症狀性膝骨關節炎與影像確認的積液滑膜炎。
- Population
- 症狀性膝骨關節炎且有積液滑膜炎的患者
- Intervention
- 薑黃萃取物每日 2 粒
- Comparator
- 相配安慰劑
- Outcome
- 相較安慰劑，VAS 疼痛改善 9.1 mm；積液滑膜炎體積未改變。
- Follow-up
- 12 週
- Formulation
- Not established
- Dose
- Curcuma longa萃取物每日2粒；摘要未報告每粒毫克數
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 13
6 週完成者分析顯示VAS、步行表現及WOMAC疼痛與身體功能相對基線改善，摘要稱優於活性比較組，但未提供完整組間數值。
Applicability assessment: CurQfen 與葡萄糖胺加軟骨素的活性對照試驗。
- Population
- 骨關節炎受試者
- Intervention
- curcumagalactomannosides 每日 400 mg
- Comparator
- 葡萄糖胺鹽酸鹽加軟骨素硫酸鹽
- Outcome
- 摘要稱低劑量 CGM 緩解骨關節炎疼痛及症狀的效果優於葡萄糖胺加軟骨素。
- Follow-up
- 6 週
- Formulation
- Not established
- Dose
- CGM 400 mg，每日1次
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 14
6 週WOMAC疼痛、總分、僵硬與功能在預定等效界限內與撲熱息痛相當；薑黃萃取物組各域亦有改善。
Applicability assessment: 膝骨關節炎的 BCM-95 與撲熱息痛活性對照試驗。
- Population
- 膝骨關節炎患者
- Intervention
- BCM-95 薑黃萃取物每次 500 mg、每日 2 次
- Comparator
- 撲熱息痛每次 650 mg、每日 3 次
- Outcome
- 在研究設定的界限內，兩組 WOMAC 各領域分數相當。
- Follow-up
- 6 週
- Formulation
- Not established
- Dose
- BCM-95薑黃萃取物500 mg，每日2次
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 15
8 週KOOS疼痛與數值疼痛評分改善；計時起立行走、6分鐘步行及JOA改善，但30秒坐站與40公尺快走未改善。
Applicability assessment: 成人膝骨關節炎的 Curcugen 安慰劑對照試驗。
- Population
- 成人膝骨關節炎患者
- Intervention
- Curcugen 標準化薑黃素萃取物每次 500 mg、每日 2 次
- Comparator
- 安慰劑
- Outcome
- 相較安慰劑，KOOS 膝痛分數與數值膝痛評分顯著下降。
- Follow-up
- 8 週
- Formulation
- Not established
- Dose
- Curcugen 500 mg，每日2次
Source excerpt: Compared to the placebo, curcumin significantly reduced the KOOS knee pain score (p = 0.009) and numeric knee pain ratings (p = 0.001).View source
Main result 16
3 個月第90日VAS降幅大於安慰劑，KOOS疼痛、日常活動、運動娛樂功能及生活品質等各域均較佳。
Applicability assessment: 輕至中度膝骨關節炎的水分散型薑黃萃取物試驗。
- Population
- 輕至中度膝骨關節炎患者
- Intervention
- WDTE60N 每日 250 mg
- Comparator
- 安慰劑
- Outcome
- 第 90 天 VAS 疼痛自基線的降幅大於安慰劑組。
- Follow-up
- 3 個月
- Formulation
- Not established
- Dose
- WDTE60N 250 mg，每日1次
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 17
8 週相較單獨標準照護，加用CurcuBoost使WOMAC疼痛、身體功能、總分及VAS疼痛改善更大。
Applicability assessment: 影像確認膝骨關節炎、在標準照護上加用 CurcuBoost 的試驗。
- Population
- 40 至 75 歲、影像確認的膝骨關節炎患者
- Intervention
- CurcuBoost 每日 500 mg 加標準照護
- Comparator
- 單獨標準照護
- Outcome
- 第 8 週，加用 CurcuBoost 的 WOMAC 疼痛降幅大於單獨標準照護。
- Follow-up
- 8 週
- Formulation
- Not established
- Dose
- CurcuBoost 500 mg，每日1次，加標準照護
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceSafety finding 18
42 天摘要僅稱耐受性與接受度較佳，未提供事件數或停藥數。
Applicability assessment: 原發性疼痛性膝骨關節炎的薑黃萃取物試驗。
- Population
- 原發性膝骨關節炎患者
- Intervention
- 薑黃素或薑黃類素（NR-INF-02）
- Comparator
- 安慰劑
- Outcome
- 摘要稱 NR-INF-02 的耐受性與接受度較佳，未在此句提供事件數。
- Follow-up
- 42 天
- Formulation
- Not established
- Dose
- NR-INF-02 500 mg，每日2次
Source excerpt: The tolerability and acceptability profile of NR-INF-02 was better during the trial period.View source
Safety finding 19
4 週兩組發生不良事件的患者數無差異，但布洛芬組腹痛或不適事件較多；摘要未報告停藥數。
Applicability assessment: 原發性膝骨關節炎與布洛芬的活性對照試驗。
- Population
- 原發性膝骨關節炎患者
- Intervention
- Curcuma domestica 萃取物
- Comparator
- 布洛芬
- Outcome
- 發生不良事件的患者數無組間差異；布洛芬組腹痛或不適事件較多。
- Follow-up
- 4 週
- Formulation
- Not established
- Dose
- Curcuma domestica萃取物1,500 mg/日
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceSafety finding 20
6 週兩組均未見重大不良作用，但摘要沒有事件數與停藥資料。
Applicability assessment: 輕至中度膝骨關節炎的薑黃類素安慰劑對照試驗。
- Population
- 輕至中度膝骨關節炎患者
- Intervention
- 薑黃類素
- Comparator
- 安慰劑
- Outcome
- 兩組均未見顯著不良作用；此句未提供事件數。
- Follow-up
- 6 週
- Formulation
- Not established
- Dose
- 薑黃類素1,500 mg/日，分3次
Source excerpt: There was no considerable adverse effect in both groups.View source
Safety finding 21
8 週未觀察到重大副作用；摘要未提供一般不良事件及停藥數。
Applicability assessment: 特定水分散型薑黃素製劑用於膝骨關節炎。
- Population
- 40 歲以上、Kellgren-Lawrence II 或 III 級膝骨關節炎患者
- Intervention
- 薑黃素或薑黃類素（Theracurmin）
- Comparator
- 安慰劑
- Outcome
- Theracurmin 治療未觀察到重大副作用。
- Follow-up
- 8 週
- Formulation
- Not established
- Dose
- Theracurmin，每日含薑黃素180 mg
Source excerpt: No major side effects were observed with Theracurmin treatment.View source
Safety finding 22
摘要稱沒有治療相關不良事件；50人中46人完成，但未說明4人退出原因。
Applicability assessment: Curene 是以 Aquasome 技術製成的膝骨關節炎試驗製劑。
- Population
- 40 至 75 歲膝骨關節炎患者
- Intervention
- 薑黃素或薑黃類素（Curene）
- Comparator
- 安慰劑
- Outcome
- 未發生治療相關不良事件。
- Follow-up
- Not established
- Formulation
- Not established
- Dose
- Curene 500 mg，每日1次
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceSafety finding 23
28 天不良反應比例為薑黃素13%、雙氯芬酸38%；摘要未報告因不良事件停藥數。
Applicability assessment: 膝骨關節炎的 BCM-95 與雙氯芬酸活性對照試驗。
- Population
- 膝骨關節炎患者
- Intervention
- 薑黃素
- Comparator
- 雙氯芬酸
- Outcome
- 薑黃素組不良反應比例為 13%，雙氯芬酸組為 38%。
- Follow-up
- 28 天
- Formulation
- Not established
- Dose
- BCM-95薑黃素500 mg，每日3次
Source excerpt: Adverse effects were significantly less in the curcumin group (13% versus 38% in the diclofenac group; P <0.01).View source
Safety finding 24
90 天薑黃素組有1人因皮疹與搔癢退出；其餘事件數未報告。
Applicability assessment: 固態脂質薑黃素顆粒製劑與布洛芬的活性對照試驗。
- Population
- 膝骨關節炎患者
- Intervention
- Longvida 固態脂質薑黃素顆粒
- Comparator
- 布洛芬加安慰劑，每日 1 次
- Outcome
- 研究組有 1 人因皮疹與搔癢退出。
- Follow-up
- 90 天
- Formulation
- Not established
- Dose
- Longvida SLCP 400 mg每日2次，每粒提供薑黃素80 mg；每日薑黃素160 mg
Source excerpt: Except one withdrawal in the study group due to rash and itching, the study drug was found safe.View source
Safety finding 25
3 個月發生產品相關不良事件的患者比例相近，但高劑量組產品相關事件總數高於安慰劑；未見嚴重不良作用，未報告停藥數。
Applicability assessment: 症狀性膝骨關節炎的兩種劑量生體最佳化薑黃萃取物試驗。
- Population
- 膝骨關節炎患者
- Intervention
- 高劑量生體最佳化薑黃萃取物
- Comparator
- 安慰劑
- Outcome
- 發生產品相關不良事件的患者比例相近，但高劑量組的產品相關事件件數高於安慰劑組。
- Follow-up
- 3 個月
- Formulation
- Not established
- Dose
- 生體最佳化Curcuma longa萃取物低劑量或高劑量；摘要未報告毫克數
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceSafety finding 26
28 天不良反應比例為合併組13%、雙氯芬酸組38%；摘要未報告停藥數。
Applicability assessment: 在相同雙氯芬酸治療下評估加用 BCM-95 薑黃類素。
- Population
- 膝骨關節炎患者
- Intervention
- 薑黃類素複合物加雙氯芬酸
- Comparator
- 單用雙氯芬酸
- Outcome
- 合併組不良反應比例為 13%，單用雙氯芬酸組為 38%。
- Follow-up
- 28 天
- Formulation
- Not established
- Dose
- BCM-95薑黃類素複合物500 mg加雙氯芬酸50 mg，每日2次
Source excerpt: Adverse effects were significantly less in curcuminoid complex plus diclofenac group (13% vs 38% in diclofenac group; P < .001).View source
Safety finding 27
12 週不良事件發生率相近：薑黃萃取物14人（39%）、安慰劑18人（53%）；可能與治療相關的事件分別為2與5件，未報告停藥。
Applicability assessment: 研究對象同時有症狀性膝骨關節炎與影像確認的積液滑膜炎。
- Population
- 症狀性膝骨關節炎且有積液滑膜炎的患者
- Intervention
- 薑黃萃取物
- Comparator
- 安慰劑
- Outcome
- 不良事件發生率兩組相近：薑黃萃取物組 14 人（39%），安慰劑組 18 人（53%）。
- Follow-up
- 12 週
- Formulation
- Not established
- Dose
- Curcuma longa萃取物每日2粒；摘要未報告每粒毫克數
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceSafety finding 28
6 週所報不良事件均輕微，薑黃萃取物組5.48%、撲熱息痛組12.68%；未報告停藥數。
Applicability assessment: 膝骨關節炎的薑黃萃取物與撲熱息痛活性對照試驗。
- Population
- 膝骨關節炎患者
- Intervention
- 薑黃萃取物
- Comparator
- 撲熱息痛
- Outcome
- 所報不良事件輕微，薑黃萃取物組為 5.48%，撲熱息痛組為 12.68%。
- Follow-up
- 6 週
- Formulation
- Not established
- Dose
- BCM-95薑黃萃取物500 mg，每日2次
Source excerpt: Adverse events reported were mild and comparatively less in the turmeric extract group (5.48%) than in the paracetamol group (12.68%).View source
Safety finding 29
3 個月研究期間共報告4件輕微不良事件；摘要未分組、未述事件類型或停藥。
Applicability assessment: 輕至中度膝骨關節炎的水分散型薑黃萃取物試驗。
- Population
- 輕至中度膝骨關節炎患者
- Intervention
- 薑黃素或薑黃類素（WDTE60N）
- Comparator
- 安慰劑
- Outcome
- 研究期間報告 4 件輕微不良事件；此句未分組。
- Follow-up
- 3 個月
- Formulation
- Not established
- Dose
- WDTE60N 250 mg，每日1次
Source excerpt: Four mild adverse events were reported during the study period.View source
Safety finding 30
8 週未報告治療相關嚴重不良事件；一般不良事件及停藥細節未提供，且50人全部完成。
Applicability assessment: 影像確認膝骨關節炎、在標準照護上加用 CurcuBoost 的試驗。
- Population
- 40 至 75 歲、影像確認的膝骨關節炎患者
- Intervention
- CurcuBoost 加標準照護
- Comparator
- 單獨標準照護
- Outcome
- 未報告治療相關嚴重不良事件。
- Follow-up
- 8 週
- Formulation
- Not established
- Dose
- CurcuBoost 500 mg，每日1次，加標準照護
Source excerpt: No treatment-related serious adverse events (SAEs) were reported.View source
Sources consulted
- Safety and efficacy of Curcuma longa extract in the treatment of painful knee osteoarthritis: a randomized placebo-controlled trial. Abstract only · 2026-09-24T13:00:30.564452Z
- The efficacy of Curcuma Longa L. extract as an adjuvant therapy in primary knee osteoarthritis: a randomized control trial. Abstract only · 2026-09-24T13:00:30.564452Z
- Efficacy and safety of Curcuma domestica extracts compared with ibuprofen in patients with knee osteoarthritis: a multicenter study. Abstract only · 2026-09-24T13:00:30.564452Z
- Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial. Abstract only · 2026-09-24T13:00:30.564452Z
- Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: a randomized, double-blind, placebo-controlled prospective study. Abstract only · 2026-09-24T13:00:30.564452Z
- A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA. Abstract only · 2026-09-24T13:00:30.564452Z
- Safety and efficacy of curcumin versus diclofenac in knee osteoarthritis: a randomized open-label parallel-arm study. Abstract only · 2026-09-24T13:00:30.564452Z
- Evaluation of the efficacy and safety of Capsule Longvida® Optimized Curcumin (solid lipid curcumin particles) in knee osteoarthritis: a pilot clinical study. Abstract only · 2026-09-24T13:00:30.564452Z
- Bio-optimized Curcuma longa extract is efficient on knee osteoarthritis pain: a double-blind multicenter randomized placebo controlled three-arm study. Abstract only · 2026-09-24T13:00:30.564452Z
- The Effect of Nanocurcumin in Improvement of Knee Osteoarthritis: A Randomized Clinical Trial. Abstract only · 2026-09-24T13:00:30.564452Z
- Efficacy and safety of combination of curcuminoid complex and diclofenac versus diclofenac in knee osteoarthritis: A randomized trial. Abstract only · 2026-09-24T13:00:30.564452Z
- Effectiveness of Curcuma longa Extract for the Treatment of Symptoms and Effusion-Synovitis of Knee Osteoarthritis : A Randomized Trial. Abstract only · 2026-09-24T13:00:30.564452Z
- Influence of a low-dose supplementation of curcumagalactomannoside complex (CurQfen) in knee osteoarthritis: A randomized, open-labeled, active-controlled clinical trial. Abstract only · 2026-09-24T13:00:30.564452Z
- Bioavailable turmeric extract for knee osteoarthritis: a randomized, non-inferiority trial versus paracetamol. Abstract only · 2026-09-24T13:00:30.564452Z
- An Investigation into the Effects of a Curcumin Extract (Curcugen®) on Osteoarthritis Pain of the Knee: A Randomised, Double-Blind, Placebo-Controlled Study. Abstract only · 2026-09-24T13:00:30.564452Z
- Efficacy and Safety of a Novel Low-Dose Water-Dispersible Turmeric Extract in the Management of Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Abstract only · 2026-09-24T13:00:30.564452Z
- Bioavailability-Enhanced Curcumin (CurcuBoost®) as Adjunct Therapy Improves Symptoms in Knee Osteoarthritis: A Randomized Clinical Trial. Abstract only · 2026-09-24T13:00:30.564452Z
Reading and assessment notes
This is an AI preliminary assessment, not expert review or formal GRADE. Read the method and common limitations.
Absence of reported harms does not establish safety. This summary does not provide individual treatment or dosing advice.
Data and assessment record
Search coverage for this case
對成人膝骨關節炎患者，口服單方薑黃素或薑黃類素作為症狀治療，相較於安慰劑、相同共照或活性對照，是否改善疼痛或身體功能，並有哪些不良反應？
Searched：2026-09-24T13:00:30.564452Z · Databases：PubMed
115 records identified; 115 screened; 17 reports from 16 unique study populations included.
Some included reports were assessed without full text.
- 部分候選文獻未取得全文，完整偏倚風險與次要結果評讀受限。
- 本次檢索限於 PubMed 與已取得全文，未進行所有資料庫與完整引文追查。
Processing record
Evidence summary available
Sources through：2026-09-24 · Generated：2026-09-24T14:22:20.518249+00:00
Retrieved 115 records · Screened 115 · Included 17 reports · Omitted 98
Run：reader-enrichment-rating-candidate-unit-projection-v5
codex_cli / gpt-5.6-sol / problem-search-source-bound-l2+l11-v1
{
"included": 17,
"limits_hit": [
"fulltext_unavailable",
"limited_citation_tracing"
],
"omitted": 98,
"retrieved": 115,
"screened": 115
} sha256:5f888d61376ab6db1e4a2a31234bf87820cbf417a8a22c206d3f41c40ff5bd32